NASDAQ:EXAS - EXACT Sciences Stock Price, Price Target & More

$45.33 -1.60 (-3.41 %)
(As of 04/25/2018 12:24 PM ET)
Previous Close$46.93
Today's Range$44.85 - $47.44
52-Week Range$23.71 - $63.60
Volume2.07 million shs
Average Volume2.84 million shs
Market Capitalization$5.89 billion
P/E Ratio-45.39
Dividend YieldN/A
Beta0.87

About EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences logoExact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:EXAS
CUSIP30063P10
Phone608-284-5700

Debt

Debt-to-Equity Ratio0.01%
Current Ratio7.15%
Quick Ratio6.77%

Price-To-Earnings

Trailing P/E Ratio-45.39
Forward P/E Ratio-49.27
P/E GrowthN/A

Sales & Book Value

Annual Sales$265.99 million
Price / Sales20.61
Cash FlowN/A
Price / CashN/A
Book Value$4.35 per share
Price / Book10.42

Profitability

EPS (Most Recent Fiscal Year)($0.99)
Net Income$-114,390,000.00
Net Margins-43.01%
Return on Equity-24.13%
Return on Assets-21.62%

Miscellaneous

Employees1,268
Outstanding Shares120,940,000

How to Become a New Pot Stock Millionaire

EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) announced its earnings results on Thursday, February, 22nd. The medical research company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.09. The medical research company earned $87.41 million during the quarter, compared to the consensus estimate of $87.42 million. EXACT Sciences had a negative net margin of 43.01% and a negative return on equity of 24.13%. EXACT Sciences's quarterly revenue was up 148.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.34) earnings per share. View EXACT Sciences' Earnings History.

When is EXACT Sciences' next earnings date?

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for EXACT Sciences.

What price target have analysts set for EXAS?

14 brokers have issued 12 month price objectives for EXACT Sciences' shares. Their predictions range from $28.00 to $67.00. On average, they expect EXACT Sciences' stock price to reach $53.2308 in the next twelve months. View Analyst Ratings for EXACT Sciences.

Are investors shorting EXACT Sciences?

EXACT Sciences saw a decline in short interest during the month of March. As of March 29th, there was short interest totalling 14,162,695 shares, a decline of 10.5% from the March 15th total of 15,832,210 shares. Based on an average daily trading volume, of 2,510,924 shares, the days-to-cover ratio is presently 5.6 days. Currently, 12.0% of the shares of the company are sold short.

Who are some of EXACT Sciences' key competitors?

Who are EXACT Sciences' key executives?

EXACT Sciences' management team includes the folowing people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 52)
  • Mr. Jeffrey T. Elliott CFA, CFO & Chief Accounting Officer (Age 40)
  • Mr. Maneesh K. Arora, Sr. VP, COO & Director (Age 49)
  • Dr. Graham P. Lidgard Ph.D., Chief Science Officer and Sr. VP of R&D (Age 69)
  • Mr. D. Scott Coward, Chief Legal Officer, Sr. VP, Gen. Counsel and Sec. (Age 53)

Has EXACT Sciences been receiving favorable news coverage?

News articles about EXAS stock have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. EXACT Sciences earned a news sentiment score of 0.01 on Accern's scale. They also gave media coverage about the medical research company an impact score of 45.02 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are EXACT Sciences' major shareholders?

EXACT Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include LONE PINE CAPITAL LLC (5.30%). Company insiders that own EXACT Sciences stock include D Scott Coward, David Thompson, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling, Maneesh Arora and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

How do I buy shares of EXACT Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EXACT Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $45.20.

How big of a company is EXACT Sciences?

EXACT Sciences has a market capitalization of $5.89 billion and generates $265.99 million in revenue each year. The medical research company earns $-114,390,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. EXACT Sciences employs 1,268 workers across the globe.

How can I contact EXACT Sciences?

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.


MarketBeat Community Rating for EXACT Sciences (EXAS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  590 (Vote Outperform)
Underperform Votes:  333 (Vote Underperform)
Total Votes:  923
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

EXACT Sciences (NASDAQ:EXAS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
14 Wall Street analysts have issued ratings and price targets for EXACT Sciences in the last 12 months. Their average twelve-month price target is $53.2308, suggesting that the stock has a possible upside of 17.43%. The high price target for EXAS is $67.00 and the low price target for EXAS is $28.00. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.642.642.77
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $53.2308$53.2308$51.8462$44.9231
Price Target Upside: 17.43% upside25.07% upside8.74% upside3.64% downside

EXACT Sciences (NASDAQ:EXAS) Consensus Price Target History

Price Target History for EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences (NASDAQ:EXAS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2018BTIG ResearchUpgradeNeutral -> BuyLowView Rating Details
3/29/2018William BlairReiterated RatingBuyN/AView Rating Details
3/28/2018Leerink SwannSet Price TargetBuy$67.00HighView Rating Details
2/27/2018Robert W. BairdUpgradeNeutral -> Outperform$42.56 -> $56.00MediumView Rating Details
2/23/2018BenchmarkDowngradeBuy -> HoldHighView Rating Details
1/29/2018Goldman SachsInitiated CoverageNeutral -> Neutral$17.77 -> $51.00LowView Rating Details
1/8/2018Bank of AmericaSet Price TargetBuy$67.00HighView Rating Details
10/31/2017Canaccord GenuityUpgradeBuy$60.00N/AView Rating Details
10/31/2017Craig HallumBoost Price TargetBuy$46.00 -> $61.00N/AView Rating Details
10/31/2017Jefferies GroupBoost Price TargetBuy$60.00N/AView Rating Details
7/26/2017Roth CapitalBoost Price TargetBuy$40.00 -> $46.00HighView Rating Details
7/26/2017Lake Street CapitalBoost Price TargetHold -> Hold$30.00 -> $41.00MediumView Rating Details
6/7/2017StephensSet Price TargetHold$28.00MediumView Rating Details
5/31/2017CowenReiterated RatingOutperform$45.00HighView Rating Details
7/27/2016MizuhoBoost Price TargetNeutral$10.00 -> $15.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

EXACT Sciences (NASDAQ:EXAS) Earnings History and Estimates Chart

Earnings by Quarter for EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences (NASDAQ:EXAS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.85)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($0.33)($0.24)($0.27)
Q2 20184($0.33)($0.18)($0.24)
Q3 20184($0.32)($0.10)($0.20)
Q4 20184($0.31)($0.03)($0.15)
Q1 20191($0.14)($0.14)($0.14)

EXACT Sciences (NASDAQ EXAS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018($0.39)N/AView Earnings Details
2/22/2018Q4 2017($0.27)($0.18)$87.42 million$87.41 millionViewListenView Earnings Details
10/30/2017Q3 2017($0.30)($0.23)$65.03 million$72.60 millionViewN/AView Earnings Details
7/25/2017Q2 2017($0.37)($0.27)$47.73 million$57.65 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.41)($0.32)$37.38 million$48.36 millionViewN/AView Earnings Details
2/21/2017Q416($0.39)($0.34)$32.53 million$35.24 millionViewListenView Earnings Details
10/26/2016Q316($0.43)($0.36)$25.24 million$28.10 millionViewListenView Earnings Details
7/26/2016Q216($0.55)($0.46)$18.54 million$21.20 millionViewListenView Earnings Details
5/3/2016Q116($0.52)($0.49)$15.17 million$14.80 millionViewN/AView Earnings Details
2/24/2016Q415($0.47)($0.41)$14.96 million$14.40 millionViewListenView Earnings Details
10/29/2015Q315($0.44)($0.45)$12.56 million$12.60 millionViewListenView Earnings Details
7/20/2015Q215($0.45)($0.44)$7.96 million$8.10 millionViewListenView Earnings Details
5/4/2015Q115($0.41)($0.40)$4.11 million$4.30 millionViewN/AView Earnings Details
2/24/2015Q414($0.39)($0.38)$19.90 million$1.15 millionViewN/AView Earnings Details
10/27/2014Q314($0.34)($0.39)$0.13 millionViewListenView Earnings Details
7/22/2014Q214($0.25)($0.24)$0.03 millionViewN/AView Earnings Details
5/1/2014Q114($0.19)($0.23)$0.40 million$0.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.19)($0.17)$1.02 million$1.00 millionViewN/AView Earnings Details
10/29/2013Q313($0.18)($0.16)$1.02 million$1.00 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.18)($0.19)$1.02 million$1.00 millionViewN/AView Earnings Details
5/1/2013Q1 2013($0.20)($0.17)$1.02 million$1.00 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.18)($0.22)$1.04 million$1.00 millionViewN/AView Earnings Details
10/30/2012Q312($0.21)($0.21)$1.03 million$1.04 millionViewN/AView Earnings Details
7/25/2012($0.20)($0.26)ViewN/AView Earnings Details
5/1/2012($0.18)($0.19)ViewN/AView Earnings Details
2/23/2012($0.17)($0.18)ViewN/AView Earnings Details
11/3/2011($0.15)($0.15)ViewN/AView Earnings Details
8/2/2011($0.10)($0.13)ViewN/AView Earnings Details
5/3/2011($0.09)($0.08)ViewN/AView Earnings Details
2/15/2011($0.08)($0.08)ViewN/AView Earnings Details
10/27/2010Q3 2010($0.08)($0.08)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.07)($0.06)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.05)($0.06)ViewN/AView Earnings Details
2/16/2010Q4 2009($0.06)($0.05)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.03)ViewN/AView Earnings Details
8/12/2009Q2 2009($0.08)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.13)ViewN/AView Earnings Details
3/30/2009Q4 2008($0.08)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.09)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.08)ViewN/AView Earnings Details
5/5/2008Q1 2008($0.09)ViewN/AView Earnings Details
2/4/2008Q4 2007($0.14)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

EXACT Sciences (NASDAQ:EXAS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

EXACT Sciences (NASDAQ EXAS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 81.96%
Insider Trading History for EXACT Sciences (NASDAQ:EXAS)
Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences (NASDAQ EXAS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/12/2018Katherine S ZanottiDirectorSell7,232$45.00$325,440.00105,814View SEC Filing  
4/10/2018Thomas D CareyDirectorSell8,448$39.73$335,639.0452,610View SEC Filing  
4/2/2018D Scott CowardSVPSell2,122$40.12$85,134.64View SEC Filing  
3/12/2018D Scott CowardSVPSell2,708$52.19$141,330.52View SEC Filing  
3/12/2018Kevin T ConroyInsiderSell11,459$52.19$598,045.21200,074View SEC Filing  
3/12/2018Maneesh AroraCOOSell5,295$52.19$276,346.05View SEC Filing  
3/9/2018Graham Peter LidgardInsiderSell6,125$50.94$312,007.50200,074View SEC Filing  
2/28/2018Graham Peter LidgardInsiderSell39,884$43.10$1,719,000.40View SEC Filing  
2/26/2018D Scott CowardSVPSell4,420$42.34$187,142.80View SEC Filing  
2/26/2018Jeffrey Thomas ElliottCFOSell2,982$42.34$126,257.88View SEC Filing  
2/26/2018Kevin T ConroyInsiderSell25,319$42.34$1,072,006.46211,183View SEC Filing  
2/26/2018Maneesh AroraCOOSell12,352$42.34$522,983.68644,621View SEC Filing  
2/9/2018Kevin T ConroyInsiderSell101,488$45.72$4,640,031.36931,540View SEC Filing  
1/23/2018Kevin T ConroyInsiderSell110,439$50.49$5,576,065.11940,491View SEC Filing  
1/12/2018Kevin T ConroyInsiderSell125,402$52.79$6,619,971.58955,454View SEC Filing  
1/3/2018D Scott CowardSVPSell1,665$52.54$87,479.1037,558View SEC Filing  
12/22/2017Kevin T ConroyInsiderSell123,512$52.58$6,494,260.96953,564View SEC Filing  
12/6/2017Kevin T ConroyInsiderSell121,849$53.45$6,512,829.05951,901View SEC Filing  
12/1/2017Graham Peter LidgardInsiderSell45,770$58.27$2,667,017.90237,820View SEC Filing  
11/21/2017Kevin T ConroyInsiderSell134,057$59.50$7,976,391.50View SEC Filing  
11/9/2017Kevin T ConroyCEOSell137,805$59.14$8,149,787.70967,867View SEC Filing  
11/1/2017Graham Peter LidgardInsiderSell45,775$53.60$2,453,540.00272,819View SEC Filing  
10/2/2017D Scott CowardSVPSell29,115$47.16$1,373,063.4064,991View SEC Filing  
10/2/2017Graham Peter LidgardInsiderSell81,025$47.16$3,821,139.00366,519View SEC Filing  
9/5/2017Graham Peter LidgardInsiderSell75,683$40.81$3,088,623.23308,377View SEC Filing  
9/1/2017Graham Peter LidgardInsiderSell45,775$41.49$1,899,204.75288,952View SEC Filing  
8/17/2017Thomas D CareyDirectorBuy2,500$37.71$94,275.0060,858View SEC Filing  
7/31/2017Jeffrey Thomas ElliottCFOSell5,846$39.41$230,390.8619,861View SEC Filing  
7/3/2017D Scott CowardSVPSell1,987$35.21$69,962.2757,603View SEC Filing  
4/3/2017D Scott CowardSVPSell1,543$23.74$36,630.8255,478View SEC Filing  
3/13/2017D Scott CowardSVPSell1,983$21.16$41,960.2850,790View SEC Filing  
3/13/2017Kevin T ConroyInsiderSell12,059$21.16$255,168.44817,239View SEC Filing  
3/13/2017Maneesh AroraCOOSell5,574$21.16$117,945.84556,339View SEC Filing  
2/27/2017D Scott CowardSVPSell7,046$21.48$151,348.0853,794View SEC Filing  
2/27/2017Graham Peter LidgardInsiderSell8,668$21.51$186,448.68314,527View SEC Filing  
2/27/2017Maneesh AroraCOOSell11,114$21.50$238,951.00535,940View SEC Filing  
1/3/2017D Scott CowardSVPSell1,535$13.61$20,891.3529,242View SEC Filing  
12/14/2016David ThompsonDirectorBuy10,000$13.84$138,400.00136,379View SEC Filing  
11/15/2016Kevin T ConroyInsiderSell600,000$17.46$10,476,000.001,340,057View SEC Filing  
11/15/2016Maneesh AroraCOOSell562,932$17.46$9,828,792.721,094,309View SEC Filing  
9/1/2016Lionel SterlingDirectorBuy5,000$18.10$90,500.00121,247View SEC Filing  
8/3/2016Katherine S ZanottiDirectorBuy3,380$17.93$60,603.40105,927View SEC Filing  
7/26/2016Graham Peter LidgardInsiderSell7,383$14.82$109,416.06227,592View SEC Filing  
7/26/2016Maneesh AroraCOOSell7,359$14.82$109,060.38538,736View SEC Filing  
4/1/2016D Scott CowardSVPSell1,685$6.62$11,154.7021,014View SEC Filing  
3/10/2016D Scott CowardSVPSell2,175$6.05$13,158.7518,501View SEC Filing  
3/10/2016Graham Peter LidgardInsiderSell3,041$6.05$18,398.05228,170View SEC Filing  
3/10/2016Maneesh AroraCOOSell4,042$6.05$24,454.10273,210View SEC Filing  
3/8/2016James Edward DoyleDirectorBuy5,000$6.43$32,150.0021,459View SEC Filing  
3/3/2016Katherine S NapierDirectorBuy3,775$5.38$20,309.5091,000View SEC Filing  
3/1/2016Kevin T ConroyCEOBuy50,000$5.00$250,000.00687,907View SEC Filing  
2/26/2016Kevin T ConroyCEOSell6,895$5.81$40,059.95637,907View SEC Filing  
2/25/2016Graham Peter LidgardInsiderSell2,997$5.52$16,543.44222,742View SEC Filing  
2/25/2016Maneesh AroraCOOSell4,099$5.52$22,626.48266,034View SEC Filing  
2/23/2016Graham Peter LidgardInsiderSell2,411$6.39$15,406.29216,903View SEC Filing  
2/23/2016Kevin T ConroyCEOSell6,866$6.39$43,873.74632,168View SEC Filing  
2/23/2016Maneesh AroraCOOSell2,556$6.39$16,332.84257,590View SEC Filing  
1/11/2016David ThompsonDirectorBuy15,000$6.99$104,850.00110,213View SEC Filing  
2/26/2015Graham Peter LidgardDirectorSell3,938$23.44$92,306.72View SEC Filing  
2/26/2015Kevin T ConroyCEOSell8,425$23.44$197,482.00View SEC Filing  
2/26/2015Maneesh AroraCOOSell3,895$23.44$91,298.80View SEC Filing  
2/24/2015Graham Peter LidgardDirectorSell4,037$22.90$92,447.30View SEC Filing  
2/24/2015Kevin T ConroyCEOSell9,798$22.90$224,374.20View SEC Filing  
2/24/2015Maneesh AroraCOOSell2,995$22.90$68,585.50View SEC Filing  
1/2/2015Graham Peter LidgardInsiderSell3,363$26.72$89,859.36View SEC Filing  
1/2/2015Kevin T ConroyCEOSell9,484$26.72$253,412.48View SEC Filing  
1/2/2015Maneesh AroraCOOSell2,495$26.72$66,666.40View SEC Filing  
10/29/2014Graham Peter LidgardInsiderSell8,015$24.68$197,810.20View SEC Filing  
7/25/2014Graham Peter LidgardVPSell11,081$15.99$177,185.19View SEC Filing  
7/25/2014Kevin T ConroyCEOSell11,336$15.99$181,262.64View SEC Filing  
7/25/2014Maneesh AroraCOOSell9,291$15.99$148,563.09View SEC Filing  
5/5/2014William MeganSVPBuy10,000$11.79$117,900.0012,522View SEC Filing  
2/24/2014Graham Peter LidgardVPSell3,160$14.07$44,461.20106,214View SEC Filing  
2/24/2014Kevin ConroyCEOSell8,708$14.07$122,521.56134,374View SEC Filing  
2/24/2014Maneesh AroraCOOSell2,662$14.07$37,454.3465,855View SEC Filing  
1/2/2014Graham Peter LidgardVPSell10,288$11.96$123,044.48102,149View SEC Filing  
1/2/2014Kevin ConroyCEOSell26,379$11.96$315,492.84123,707View SEC Filing  
1/2/2014Maneesh AroraCOOSell8,627$11.96$103,178.9261,292View SEC Filing  
10/28/2013Graham Peter LidgardVPSell7,430$11.07$82,250.10View SEC Filing  
9/20/2013Sally CrawfordDirectorSell25,000$12.19$304,750.00203,866View SEC Filing  
11/2/2012Kevin T ConroyCEOBuy2,000$9.13$18,260.00View SEC Filing  
11/2/2012Maneesh AroraCFOBuy1,000$9.04$9,040.00View SEC Filing  
11/1/2012Lionel SterlingDirectorBuy5,500$9.08$49,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

EXACT Sciences (NASDAQ EXAS) News Headlines

Source:
DateHeadline
Dont Get Greedy With Exact Sciences Corporation StockDon't Get Greedy With Exact Sciences Corporation Stock
finance.yahoo.com - April 25 at 8:19 AM
Don't Get Greedy With Exact Sciences Corporation StockDon't Get Greedy With Exact Sciences Corporation Stock
finance.yahoo.com - April 25 at 8:19 AM
EXACT Sciences (EXAS) Lifted to Strong-Buy at VetrEXACT Sciences (EXAS) Lifted to Strong-Buy at Vetr
www.americanbankingnews.com - April 20 at 10:18 PM
EXACT Sciences (EXAS) Upgraded to "Buy" by BidaskClubEXACT Sciences (EXAS) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - April 20 at 11:39 AM
EXACT Sciences Co. (EXAS) Given Average Recommendation of "Buy" by BrokeragesEXACT Sciences Co. (EXAS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 19 at 5:40 PM
EXACT Sciences (EXAS) Stock Rating Lowered by VetrEXACT Sciences (EXAS) Stock Rating Lowered by Vetr
www.americanbankingnews.com - April 19 at 9:23 AM
EXACT Sciences (EXAS) Scheduled to Post Earnings on ThursdayEXACT Sciences (EXAS) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - April 19 at 2:34 AM
$86.09 Million in Sales Expected for EXACT Sciences Co. (EXAS) This Quarter$86.09 Million in Sales Expected for EXACT Sciences Co. (EXAS) This Quarter
www.americanbankingnews.com - April 19 at 1:54 AM
BTIG Research Reaffirms "Buy" Rating for EXACT Sciences (EXAS)BTIG Research Reaffirms "Buy" Rating for EXACT Sciences (EXAS)
www.americanbankingnews.com - April 17 at 11:58 PM
Zacks: Analysts Expect EXACT Sciences Co. (EXAS) Will Announce Earnings of -$0.39 Per ShareZacks: Analysts Expect EXACT Sciences Co. (EXAS) Will Announce Earnings of -$0.39 Per Share
www.americanbankingnews.com - April 17 at 11:08 PM
EXACT Sciences Breaks Above 200-Day Moving Average - Bullish for EXASEXACT Sciences Breaks Above 200-Day Moving Average - Bullish for EXAS
www.nasdaq.com - April 17 at 5:56 PM
Lake Street Capital Raises EXACT Sciences (EXAS) Price Target to $41.00Lake Street Capital Raises EXACT Sciences (EXAS) Price Target to $41.00
www.americanbankingnews.com - April 15 at 8:54 PM
EXACT Sciences (EXAS) Upgraded at VetrEXACT Sciences (EXAS) Upgraded at Vetr
www.americanbankingnews.com - April 14 at 1:27 PM
Vetr Lowers EXACT Sciences (EXAS) to HoldVetr Lowers EXACT Sciences (EXAS) to Hold
www.americanbankingnews.com - April 14 at 12:17 AM
Insider Selling: EXACT Sciences Co. (EXAS) Director Sells 7,232 Shares of StockInsider Selling: EXACT Sciences Co. (EXAS) Director Sells 7,232 Shares of Stock
www.americanbankingnews.com - April 13 at 10:10 PM
Short Interest in EXACT Sciences Co. (EXAS) Decreases By 10.5%Short Interest in EXACT Sciences Co. (EXAS) Decreases By 10.5%
www.americanbankingnews.com - April 13 at 3:43 AM
Thomas D. Carey Sells 8,448 Shares of EXACT Sciences Co. (EXAS) StockThomas D. Carey Sells 8,448 Shares of EXACT Sciences Co. (EXAS) Stock
www.americanbankingnews.com - April 12 at 4:33 PM
Noteworthy Tuesday Option Activity: GM, EXAS, TMUSNoteworthy Tuesday Option Activity: GM, EXAS, TMUS
www.nasdaq.com - April 10 at 5:30 PM
Today’s Research Reports on Trending Tickers: Exact Sciences and ExelixisToday’s Research Reports on Trending Tickers: Exact Sciences and Exelixis
finance.yahoo.com - April 10 at 8:25 AM
Exact Sciences schedules first-quarter 2018 earnings callExact Sciences schedules first-quarter 2018 earnings call
finance.yahoo.com - April 9 at 8:18 AM
Exact Sciences Corporation Could Break Out Despite Steep Drop in BiotechExact Sciences Corporation Could Break Out Despite Steep Drop in Biotech
investorplace.com - April 9 at 5:54 AM
Is Exact Sciences Corp. Still a Buy in 2018?Is Exact Sciences Corp. Still a Buy in 2018?
finance.yahoo.com - April 8 at 6:01 PM
Biotechs Exact Sciences Seen Plunging 25%Biotech's Exact Sciences Seen Plunging 25%
finance.yahoo.com - April 6 at 5:42 PM
EXACT Sciences Co. (EXAS) SVP D Scott Coward Sells 2,122 SharesEXACT Sciences Co. (EXAS) SVP D Scott Coward Sells 2,122 Shares
www.americanbankingnews.com - April 3 at 10:46 PM
BTIG Expects 55% Upside In Exact SciencesBTIG Expects 55% Upside In Exact Sciences
www.benzinga.com - April 3 at 5:36 PM
ValuEngine Upgrades EXACT Sciences (EXAS) to BuyValuEngine Upgrades EXACT Sciences (EXAS) to Buy
www.americanbankingnews.com - April 3 at 4:16 PM
EXACT Sciences (EXAS) Stock Rating Upgraded by BTIG ResearchEXACT Sciences (EXAS) Stock Rating Upgraded by BTIG Research
www.americanbankingnews.com - April 3 at 7:48 AM
Leerink Swann Reaffirms "Outperform" Rating for EXACT Sciences (EXAS)Leerink Swann Reaffirms "Outperform" Rating for EXACT Sciences (EXAS)
www.americanbankingnews.com - April 2 at 9:12 PM
EXACT Sciences (EXAS) Given New $60.00 Price Target at Jefferies GroupEXACT Sciences (EXAS) Given New $60.00 Price Target at Jefferies Group
www.americanbankingnews.com - April 2 at 9:12 PM
EXACT Sciences (EXAS) Raised to Buy at Canaccord GenuityEXACT Sciences (EXAS) Raised to Buy at Canaccord Genuity
www.americanbankingnews.com - April 2 at 7:03 PM
EXACT Sciences (EXAS) Downgraded by BTIG ResearchEXACT Sciences (EXAS) Downgraded by BTIG Research
www.americanbankingnews.com - April 2 at 3:15 PM
$85.59 Million in Sales Expected for EXACT Sciences Co. (EXAS) This Quarter$85.59 Million in Sales Expected for EXACT Sciences Co. (EXAS) This Quarter
www.americanbankingnews.com - April 2 at 1:46 AM
EXACT Sciences Co. (EXAS) Expected to Post Earnings of -$0.39 Per ShareEXACT Sciences Co. (EXAS) Expected to Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - March 31 at 11:10 PM
EXACT Sciences (EXAS) Given a $67.00 Price Target at Bank of AmericaEXACT Sciences (EXAS) Given a $67.00 Price Target at Bank of America
www.americanbankingnews.com - March 30 at 2:23 PM
William Blair Reaffirms Buy Rating for EXACT Sciences (EXAS)William Blair Reaffirms Buy Rating for EXACT Sciences (EXAS)
www.americanbankingnews.com - March 30 at 1:49 PM
EXACT Sciences (EXAS) Raised to "Buy" at Zacks Investment ResearchEXACT Sciences (EXAS) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 28 at 6:32 PM
EXACT Sciences (EXAS) Downgraded by BidaskClubEXACT Sciences (EXAS) Downgraded by BidaskClub
www.americanbankingnews.com - March 28 at 11:27 AM
Leerink Swann Analysts Give EXACT Sciences (EXAS) a $67.00 Price TargetLeerink Swann Analysts Give EXACT Sciences (EXAS) a $67.00 Price Target
www.americanbankingnews.com - March 28 at 11:01 AM
BidaskClub Upgrades EXACT Sciences (EXAS) to Strong-BuyBidaskClub Upgrades EXACT Sciences (EXAS) to Strong-Buy
www.americanbankingnews.com - March 25 at 9:31 AM
EXACT Sciences (EXAS) Lifted to "Outperform" at Robert W. BairdEXACT Sciences (EXAS) Lifted to "Outperform" at Robert W. Baird
www.americanbankingnews.com - March 24 at 11:12 PM
EXACT Sciences (EXAS) Downgraded to "Hold" at BidaskClubEXACT Sciences (EXAS) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 24 at 4:30 PM
Biotricity: A Little Known Stock That Could Be The Next AXGN or EXASBiotricity: A Little Known Stock That Could Be The Next AXGN or EXAS
finance.yahoo.com - March 23 at 8:17 AM
Edited Transcript of EXAS earnings conference call or presentation 22-Feb-18 10:00pm GMTEdited Transcript of EXAS earnings conference call or presentation 22-Feb-18 10:00pm GMT
finance.yahoo.com - March 22 at 5:37 PM
Mark Stenhouse to join Exact Sciences as President, Cologuard - PR Newswire (press release)Mark Stenhouse to join Exact Sciences as President, Cologuard - PR Newswire (press release)
www.prnewswire.com - March 22 at 8:23 AM
Exact Sciences names president to lead Cologuard productExact Sciences names president to lead Cologuard product
finance.yahoo.com - March 21 at 8:45 AM
Harry Connick Jr. Hasnt Gotten Investors Jazzed Up About Exact Sciences -- Should They Be? - Motley FoolHarry Connick Jr. Hasn't Gotten Investors Jazzed Up About Exact Sciences -- Should They Be? - Motley Fool
www.fool.com - March 20 at 8:26 AM
Waiting For The Next Overreaction With Exact Sciences - Seeking AlphaWaiting For The Next Overreaction With Exact Sciences - Seeking Alpha
seekingalpha.com - March 20 at 8:26 AM
Mark Stenhouse to join Exact Sciences as President, CologuardMark Stenhouse to join Exact Sciences as President, Cologuard
finance.yahoo.com - March 20 at 8:26 AM
Harry Connick Jr. Hasn't Gotten Investors Jazzed Up About Exact Sciences -- Should They Be?Harry Connick Jr. Hasn't Gotten Investors Jazzed Up About Exact Sciences -- Should They Be?
finance.yahoo.com - March 20 at 8:26 AM
EXACT Sciences (EXAS) Upgraded by Zacks Investment Research to HoldEXACT Sciences (EXAS) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 19 at 10:40 PM

SEC Filings

EXACT Sciences (NASDAQ:EXAS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

EXACT Sciences (NASDAQ:EXAS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

EXACT Sciences (NASDAQ EXAS) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.